Telotristat ethyl

(Xermelo®)

Xermelo®

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormTablet (oral: 250 mg)
Drug Classtryptophan hydroxylase Inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Telotristat ethyl (Xermelo) is indicated for the treatment of carcinoid syndrome diarrhea in adults inadequately controlled by somatostatin analog (SSA) therapy. It has been found to reduce bowel movements in 40% of patients with diarrhea refractory to SSA, making it a valuable option for those experiencing refractory symptoms.
  • Two studies provided information about the safety and effectiveness of Xermelo compared to other treatments such as Somatostatin Analogs, Liver-Directed Therapy, Interferon-alpha, Radionuclide Therapy, and Chemotherapy.
  • Compared to these treatments, Xermelo showed specific efficacy in reducing bowel movements among patients who did not respond well enough to SSA therapy. This indicates its distinct role within a comprehensive treatment regimen for carcinoid syndrome diarrhea.
  • Interventions including telotristat ethyl are generally well tolerated with few serious adverse events reported. This suggests that this drug can be safely used alongside higher doses of SSAs or when other therapies fail.
  • No explicit subgroup considerations were mentioned apart from those patients who are resistant to SSA therapy. Future studies should focus on understanding how different populations may react differently towards this medication based on factors like age or disease severity/staging.
  • Both studies underscored the need for more high-quality randomized controlled trials focused on treating carcinoid syndrome symptoms along with standardized guidelines regarding optimal use and sequencing of drugs like telotristat ethyl within broader treatment regimens.

Product Monograph / Prescribing Information

Document TitleYearSource
Xermelo (telotristat ethyl) Prescribing Information.2022Lexicon Pharmaceuticals, Inc., The Woodlands, TX

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Carcinoid syndrome: Updates and review of current therapy. 2019Current Treatment Options in Oncology